Bio-Techne's earnings call highlighted solid organic growth and strategic positioning in core markets, especially in biopharma and cell therapy. However, uncertainties in academic funding, biotech market challenges, and policy-related headwinds create a cautious outlook.

Company Guidance -

Q1 2026

During Bio-Techne's earnings call for the fourth quarter and fiscal year 2025, several key metrics and strategic insights were shared. The company reported a 3% organic revenue growth for the quarter, driven by strength in the biopharma end markets, particularly with large pharmaceutical customers. This growth capped a fiscal year with an overall 5% organic revenue increase. The company's operational efficiencies resulted in an adjusted operating margin of 32% for the quarter. Bio-Techne announced the divestiture of its Exosome Diagnostics business to MDxHealth, which is expected to close in fiscal Q1 2026 and will deliver an immediate uplift to its operating margin profile. In terms of geographic performance, China delivered low double-digit growth in the quarter, and the Protein Sciences segment saw 4% growth, fueled by demand for proteomic analytical tools and cell therapy solutions. Despite uncertainties, the company remains confident in its long-term growth trajectory, expecting an adjusted operating margin expansion of approximately 100 basis points in fiscal 2026.

Organic Revenue Growth

Bio-Techne delivered 3% organic revenue growth in Q4 and 5% for the full fiscal year, driven by strong performance in the biopharma end markets.

Strong Performance in Biopharma

High single-digit growth in biopharma end markets, especially among large pharmaceutical customers, despite uncertainties in the pharma landscape.

Operating Margin Achievements

Achieved an adjusted operating margin of 32% for the quarter, with plans for a 100 basis point expansion in fiscal year '26.

Growth in Protein Sciences

The Protein Sciences segment reported 4% growth for Q4 and 5% for the full fiscal year, driven by demand for proteomic analytical tools and cell therapy solutions.

Cell Therapy Demand

Strong demand for Bio-Techne's GMP reagents, with a 20% growth in Q4 and over 30% growth for the full fiscal year.

China Market Recovery

China delivered low double-digit growth in Q4, showing signs of stabilization and modest growth potential.

Divestiture of Exosome Diagnostics

Strategic divestiture of Exosome Diagnostics to MDxHealth, expected to improve operating margin and focus on core growth pillars.

Bio-Techne (TECH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TECH Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 04, 2025	2026 (Q1)	0.42 / -	0.42	―	―	―
Aug 06, 2025	2025 (Q4)	0.50 / 0.53	0.49	8.16% (+0.04)	―
May 07, 2025	2025 (Q3)	0.51 / 0.56	0.48	16.67% (+0.08)	―
Feb 05, 2025	2025 (Q2)	0.39 / 0.42	0.4	5.00% (+0.02)	―
Oct 30, 2024	2025 (Q1)	0.38 / 0.42	0.41	2.44% (+0.01)	―
Aug 07, 2024	2024 (Q4)	0.49 / 0.49	0.55	-10.91% (-0.06)	―
May 01, 2024	2024 (Q3)	0.45 / 0.48	0.53	-9.43% (-0.05)	―
Feb 01, 2024	2024 (Q2)	0.41 / 0.40	0.47	-14.89% (-0.07)	―
Oct 31, 2023	2024 (Q1)	0.43 / 0.41	0.445	-7.87% (-0.04)	―
Aug 08, 2023	2023 (Q4)	0.55 / 0.55	0.512	7.42% (+0.04)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TECH Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$54.64	$49.87	-8.73%
May 07, 2025	$47.64	$48.67	+2.16%
Feb 05, 2025	$72.34	$75.04	+3.73%
Oct 30, 2024	$70.47	$75.72	+7.45%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Bio-Techne (TECH) report earnings?

Bio-Techne (TECH) is schdueled to report earning on Nov 04, 2025, Before Open (Confirmed).

What is Bio-Techne (TECH) earnings time?

Bio-Techne (TECH) earnings time is at Nov 04, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TECH EPS forecast?

TECH EPS forecast for the fiscal quarter 2026 (Q1) is 0.42.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing